Apomorphine (Apokyn®)

Apokyn (apomorphine) is covered only for the FDA‑approved acute, intermittent treatment of hypomobility "off" episodes in advanced Parkinson’s disease and not for off‑label uses. Approval (up to 12 months) requires current carbidopa/levodopa therapy, documentation of intolerance or inadequate response to at least one other "off" therapy, neurologist prescribing or consult, subcutaneous administration with titration from 2 mg up to 6 mg, and documentation of diagnosis and applicable safety criteria.

"Apokyn (apomorphine) is indicated for the acute, intermittent treatment of hypomobility "off" episodes ("end-of-dose wearing off" and unpredictable "on/off" episodes) with advanced Parkinson's dise..."

Sign up to see full coverage criteria, indications, and limitations.